Cargando…

Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients

Immunocompromised patients have a high risk of death from SARS-CoV-2 infection. Vaccination with an mRNA vaccine may protect these patients against severe COVID-19. Several studies have evaluated the impact of immune-suppressive drug regimens on cellular and humoral responses to SARS-CoV-2 variants...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiedemann, Aurélie, Pellaton, Céline, Dekeyser, Manon, Guillaumat, Lydia, Déchenaud, Marie, Krief, Corinne, Lacabaratz, Christine, Grimbert, Philippe, Pantaleo, Giuseppe, Lévy, Yves, Durrbach, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441691/
https://www.ncbi.nlm.nih.gov/pubmed/36072955
http://dx.doi.org/10.3389/fmed.2022.978764
_version_ 1784782638695841792
author Wiedemann, Aurélie
Pellaton, Céline
Dekeyser, Manon
Guillaumat, Lydia
Déchenaud, Marie
Krief, Corinne
Lacabaratz, Christine
Grimbert, Philippe
Pantaleo, Giuseppe
Lévy, Yves
Durrbach, Antoine
author_facet Wiedemann, Aurélie
Pellaton, Céline
Dekeyser, Manon
Guillaumat, Lydia
Déchenaud, Marie
Krief, Corinne
Lacabaratz, Christine
Grimbert, Philippe
Pantaleo, Giuseppe
Lévy, Yves
Durrbach, Antoine
author_sort Wiedemann, Aurélie
collection PubMed
description Immunocompromised patients have a high risk of death from SARS-CoV-2 infection. Vaccination with an mRNA vaccine may protect these patients against severe COVID-19. Several studies have evaluated the impact of immune-suppressive drug regimens on cellular and humoral responses to SARS-CoV-2 variants of concern in this context. We performed a prospective longitudinal study assessing specific humoral (binding and neutralizing antibodies against spike (S) and T-lymphocyte (cytokine secretion and polyfunctionality) immune responses to anti-COVID-19 vaccination with at least two doses of BNT162b2 mRNA vaccine in stable kidney transplant recipients (KTR) on calcineurin inhibitor (CNI)- or belatacept-based treatment regimens. Fifty-two KTR−31 receiving CNI and 21 receiving belatacept—were enrolled in this study. After two doses of vaccine, 46.9% of patients developed anti-S IgG. Anti-spike IgG antibodies were produced in only 21.4% of the patients in the belatacept group, vs. 83.3% of those in the CNI group. The Beta and Delta variants and, more importantly, the Omicron variant, were less well neutralized than the Wuhan strain. T-cell functions were also much weaker in the belatacept group than in the CNI group. Renal transplant patients have an impaired humoral response to BNT162b2 vaccination. Belatacept-based regimens severely weaken both humoral and cellular vaccine responses. Clinically, careful evaluations of at least binding IgG responses, and prophylactic or post-exposure strategies are strongly recommended for transplant recipients on belatacept-based regimens.
format Online
Article
Text
id pubmed-9441691
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94416912022-09-06 Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients Wiedemann, Aurélie Pellaton, Céline Dekeyser, Manon Guillaumat, Lydia Déchenaud, Marie Krief, Corinne Lacabaratz, Christine Grimbert, Philippe Pantaleo, Giuseppe Lévy, Yves Durrbach, Antoine Front Med (Lausanne) Medicine Immunocompromised patients have a high risk of death from SARS-CoV-2 infection. Vaccination with an mRNA vaccine may protect these patients against severe COVID-19. Several studies have evaluated the impact of immune-suppressive drug regimens on cellular and humoral responses to SARS-CoV-2 variants of concern in this context. We performed a prospective longitudinal study assessing specific humoral (binding and neutralizing antibodies against spike (S) and T-lymphocyte (cytokine secretion and polyfunctionality) immune responses to anti-COVID-19 vaccination with at least two doses of BNT162b2 mRNA vaccine in stable kidney transplant recipients (KTR) on calcineurin inhibitor (CNI)- or belatacept-based treatment regimens. Fifty-two KTR−31 receiving CNI and 21 receiving belatacept—were enrolled in this study. After two doses of vaccine, 46.9% of patients developed anti-S IgG. Anti-spike IgG antibodies were produced in only 21.4% of the patients in the belatacept group, vs. 83.3% of those in the CNI group. The Beta and Delta variants and, more importantly, the Omicron variant, were less well neutralized than the Wuhan strain. T-cell functions were also much weaker in the belatacept group than in the CNI group. Renal transplant patients have an impaired humoral response to BNT162b2 vaccination. Belatacept-based regimens severely weaken both humoral and cellular vaccine responses. Clinically, careful evaluations of at least binding IgG responses, and prophylactic or post-exposure strategies are strongly recommended for transplant recipients on belatacept-based regimens. Frontiers Media S.A. 2022-08-22 /pmc/articles/PMC9441691/ /pubmed/36072955 http://dx.doi.org/10.3389/fmed.2022.978764 Text en Copyright © 2022 Wiedemann, Pellaton, Dekeyser, Guillaumat, Déchenaud, Krief, Lacabaratz, Grimbert, Pantaleo, Lévy and Durrbach. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Wiedemann, Aurélie
Pellaton, Céline
Dekeyser, Manon
Guillaumat, Lydia
Déchenaud, Marie
Krief, Corinne
Lacabaratz, Christine
Grimbert, Philippe
Pantaleo, Giuseppe
Lévy, Yves
Durrbach, Antoine
Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients
title Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients
title_full Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients
title_fullStr Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients
title_full_unstemmed Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients
title_short Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients
title_sort longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to covid-19 vaccination in kidney transplant recipients
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441691/
https://www.ncbi.nlm.nih.gov/pubmed/36072955
http://dx.doi.org/10.3389/fmed.2022.978764
work_keys_str_mv AT wiedemannaurelie longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients
AT pellatonceline longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients
AT dekeysermanon longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients
AT guillaumatlydia longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients
AT dechenaudmarie longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients
AT kriefcorinne longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients
AT lacabaratzchristine longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients
AT grimbertphilippe longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients
AT pantaleogiuseppe longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients
AT levyyves longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients
AT durrbachantoine longitudinalevaluationoftheimpactofimmunosuppressiveregimenonimmuneresponsestocovid19vaccinationinkidneytransplantrecipients